石四药集团(02005)：复合磷酸氢钾注射液获国家药监局的药品生产注册批件

Group 1 - The core point of the article is that Stone Four Pharmaceutical Group has obtained a production registration approval from the National Medical Products Administration of China for a new 2ml specification of compound potassium hydrogen phosphate injection, classified as a Class 3 chemical drug and considered to have passed the consistency evaluation [1] Group 2 - The compound potassium hydrogen phosphate injection is a compound preparation used to correct hypophosphatemia in adult and pediatric patients when oral or enteral nutrition is insufficient, contraindicated, or not feasible, and is also used for parenteral nutrition in these patients [1]